ESCs/iPSCs

Researchers describe "region-selective" pluripotent stem cells from mouse and humans, and highlight their therapeutic potential.

A non-nucleic acid based reprogramming strategy promises to provide a safe and effective treatment for lost retinal cells in glaucoma sufferers.

Researchers use matched human embryonic stem cell lines to understand the perturbed developmental mechanisms which lead to heart defects in Down's Syndrome patients.

The implementation of mass cytometry analysis to the reprogramming process has illuminated the early chaotic stages of reprogramming and has uncovered essential new pathways controlling the process.

Researchers combine multiple stem/progenitor types to generate miniature functional organ “buds” which may be useful in developmental and disease modelling, and in the future, tissue replacement.

Gene editing technology, combined with iPSC generation and a clinically relevant differentiation strategy combine to offer a new treatment for a blood borne genetic disease

Researchers take the first steps towards creating a clinically-relevant source of platelets from human induced pluripotent stem cells.

For the first time, researchers demonstrate long term success of a cell replacement therapy using autologous induced pluripotent stem cell derivatives

A new strategy to create patient specific induced pluripotent stem cells brings these cells closer to application in the clinic.

Researchers find that altering human ESC expansion medium can alter subsequent differentiation potential in a reversible manner